Institut National De La Sante Et De La Recherche Medicale

Centre National De La Recherche Scientifique

Dana-farber-cancer Institute Inc.

Université De Bretagne Occidentale

Mablife

Monoclonal Antibodies Therapeutics

University Health Network

Inserm

Laurence Boumsell

Armand Bensussan

Allessandro Moretta

Martine Bagot

Jean Kadouche

Gordon James Freeman

Lee M Nadler

Vassiliki A Boussiotis

Marie-Françoise Belin

Joachim L Schultze

Christian Berthou

Pascale Giraudon

Kathryn T Hall

Karine Lester

Phillipe Le Bouteiller

Martine Cerruti

Severine Loisel

John E Dick

Séverine Loisel

Florence Smadja

The present invention relates to compositions containing antibodies for treating CD5+ HLA-DR+ B OR T cell related diseases such as B or T cell malignances (leukaemia and lymphoma), autoimmune diseases and T cell related diseases as transplantation and graft rejection.

Compositions containing antibodies for treating CD5+ HLA-DR+ B or T cell related diseases

The invention relates to a novel molecule, termed SC5 by the inventors, to a novel allelic form of p140, and to the biological applications of SC5 and p140 molecules, notably in the diagnosis and therapy of CTCL.

Means for the diagnosis and therapy of CTCL

The present invention relates to biological and medical applications of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) and of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD160 compounds in the fields of EC angiogenesis, and NK and T cytokine production.

Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2

The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric anti-CD71 monoclonal antibodies, advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 antibodies, as well as pharmaceutical compositions containing them, are useful for inhibiting proliferation and/or killing malignant tumour cells, especially metastatic cutaneous and uveal melanoma cells.

Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells

The invention relates to the use a BD16 and/or BB18 anti-CD100 antibody or of a chimeric or humanized or human form thereof, or a fragment thereof, for the therapy or diagnosis of a central nervous system disorder, more particularly a myelin disorder or a disease that affects oligodendrocytes, such as multiple sclerosis or HTLV-1 associated myelopathy or peripheral myelinating cells.

Use of anti-CD100 antibodies for the treatment of inflammatory disorders affecting the central or peripheral nervous system

The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric anti-CD71 monoclonal antibodies, advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 antibodies, as well as pharmaceutical compositions containing them, are useful for inhibiting proliferation and/or killing malignant tumor cells, especially metastatic cutaneous and uveal melanoma cells.

Isolated nucleic acid molecules encoding novel CD100 molecules which stimulate a leukocyte response, such as a B cell response, including B cell aggregation, B cell differentiation, B cell survival, and/or T cell proliferation are disclosed. These novel molecules have a certain homology to semaphorins, proteins which are growth cone guidance molecules that are critical for guiding growing axons of neurons to their targets. In addition to isolated nucleic acids molecules, antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced are also described. The invention further provides isolated CD100 proteins, fusion proteins and active fragments thereof. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Nucleic acids encoding CD100 molecules

A means for the diagnosis and therapy of T lymphomas, in particular Cutaneous T Cell Lymphomas ('CTCL') are provided. Tumor markers which are universal for CTCL are described. More particularly, a molecule, termed SC5 by the inventors, an allelic form of p140, and biological applications of SC5 and p140 molecules, notably in the diagnosis and therapy of CTCL are described.

Growing community of inventors

Paris, France

Laurence Boumsell